An LRP5 receptor with internal deletion in hyperparathyroid tumors with implications for deregulated WNT/β-catenin signaling
2007

Truncated LRP5 Receptor in Hyperparathyroid Tumors

Sample size: 57 publication Evidence: high

Author Information

Author(s): Björklund P, Åkerström G, Westin G

Primary Institution: Uppsala University Hospital, Uppsala, Sweden

Hypothesis

What role does the internally truncated LRP5 receptor play in the activation of the WNT/β-catenin signaling pathway in hyperparathyroid tumors?

Conclusion

The internally truncated LRP5 receptor is implicated in the deregulated activation of the WNT/β-catenin signaling pathway in hyperparathyroid tumors.

Supporting Evidence

  • 86% of primary hyperparathyroid tumors expressed the truncated LRP5 receptor.
  • 100% of secondary hyperparathyroid tumors expressed the truncated LRP5 receptor.
  • Expression of the truncated LRP5 receptor was required for maintaining active β-catenin levels.

Takeaway

Some tumors in the parathyroid glands have a broken version of a protein called LRP5, which helps control cell growth. This broken protein might be causing the tumors to grow too much.

Methodology

The study involved analyzing parathyroid tumors for the expression of LRP5 and β-catenin using PCR and Western blotting, and assessing the effects of LRP5 on cell growth in vitro and in a mouse model.

Limitations

The study does not explore the exact mechanisms by which the truncated LRP5 receptor activates β-catenin signaling.

Participant Demographics

Patients with primary hyperparathyroidism (pHPT) and secondary hyperparathyroidism (sHPT) were included.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1371/journal.pmed.0040328

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication